HK1258520A1 - 用於指導血壓下降療法的腎上腺髓質素 - Google Patents

用於指導血壓下降療法的腎上腺髓質素

Info

Publication number
HK1258520A1
HK1258520A1 HK19100872.2A HK19100872A HK1258520A1 HK 1258520 A1 HK1258520 A1 HK 1258520A1 HK 19100872 A HK19100872 A HK 19100872A HK 1258520 A1 HK1258520 A1 HK 1258520A1
Authority
HK
Hong Kong
Prior art keywords
adrenomedullin
blood pressure
pressure decline
guide therapy
therapy
Prior art date
Application number
HK19100872.2A
Other languages
English (en)
Inventor
安德里亞斯‧伯格曼
Original Assignee
斯弗因高泰克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 斯弗因高泰克有限公司 filed Critical 斯弗因高泰克有限公司
Publication of HK1258520A1 publication Critical patent/HK1258520A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
HK19100872.2A 2013-03-20 2019-01-17 用於指導血壓下降療法的腎上腺髓質素 HK1258520A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13160265 2013-03-20

Publications (1)

Publication Number Publication Date
HK1258520A1 true HK1258520A1 (zh) 2019-11-15

Family

ID=47901848

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16104224.2A HK1216264A1 (zh) 2013-03-20 2016-04-13 用於指導血壓下降療法的腎上腺髓質素
HK19100872.2A HK1258520A1 (zh) 2013-03-20 2019-01-17 用於指導血壓下降療法的腎上腺髓質素

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16104224.2A HK1216264A1 (zh) 2013-03-20 2016-04-13 用於指導血壓下降療法的腎上腺髓質素

Country Status (11)

Country Link
US (2) US10598674B2 (zh)
EP (1) EP2976646B1 (zh)
JP (3) JP6259905B2 (zh)
CN (2) CN108362885B (zh)
CA (1) CA2907467A1 (zh)
DK (1) DK2976646T3 (zh)
ES (1) ES2830036T3 (zh)
HK (2) HK1216264A1 (zh)
RU (1) RU2673455C2 (zh)
SG (2) SG11201507774YA (zh)
WO (1) WO2014147153A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018010269A2 (pt) * 2015-11-27 2019-02-05 Brahms Gmbh mr-proadm como marcador para o status do volume extracelular de um indivíduo
CN109716136B (zh) * 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
JP6855118B2 (ja) * 2017-03-14 2021-04-07 東ソー株式会社 全身状態の良不良を評価するための情報を提供する方法及び測定試薬
WO2018181638A1 (ja) * 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
CN107194129B (zh) * 2017-06-30 2019-08-06 江南大学 一种应用乳酸修正的adm1模型分析餐厨垃圾产甲烷的方法
EP3438668A1 (en) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
JP7258860B2 (ja) * 2017-09-13 2023-04-17 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
WO2019053115A1 (en) * 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
PL3682247T3 (pl) 2017-09-13 2022-04-25 B.R.A.H.M.S Gmbh Proadrenomedulina jako marker nieprawidłowych poziomów płytek krwi
EP4159230A1 (en) * 2017-09-25 2023-04-05 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
CN111480076A (zh) * 2017-10-18 2020-07-31 艾德里诺医药公司 抗肾上腺髓质素（adm）结合剂治疗下的疗法监测
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
EP3729083A1 (en) * 2017-12-20 2020-10-28 B.R.A.H.M.S GmbH Antibiotic therapy guidance based on pro-adm
EP3578989A1 (en) * 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
CA3119792A1 (en) * 2018-11-15 2020-05-22 Ferring B.V. Compounds, compositions and methods for treating sepsis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8519425D0 (en) 1985-08-01 1985-09-04 Ici Plc Amine production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
DK1531791T3 (da) 2002-06-07 2010-11-01 Dyax Corp Forebyggelse og begrænsning af iskæmi
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
US20090304673A1 (en) * 2008-06-10 2009-12-10 Bernd Buchberger Method of Treatment of Inflammatory Diseases
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
US20120301393A1 (en) 2009-12-14 2012-11-29 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
BR112012032406A2 (pt) * 2010-06-18 2016-10-25 Cezanne S A S marcadores para o prognóstico e avaliação de risco de hipertensão induzida pela gravidez e pré-eclâmpsia

Also Published As

Publication number Publication date
RU2015144699A (ru) 2017-04-28
CN108362885B (zh) 2021-05-14
HK1216264A1 (zh) 2016-10-28
ES2830036T3 (es) 2021-06-02
DK2976646T3 (da) 2020-11-16
CN108362885A (zh) 2018-08-03
EP2976646A1 (en) 2016-01-27
JP6820399B2 (ja) 2021-01-27
CA2907467A1 (en) 2014-09-25
EP2976646B1 (en) 2020-08-19
JP6259905B2 (ja) 2018-01-10
CN105102985B (zh) 2018-05-18
JP2016521351A (ja) 2016-07-21
CN105102985A (zh) 2015-11-25
JP2018059947A (ja) 2018-04-12
SG10201800309SA (en) 2018-02-27
US20170010286A1 (en) 2017-01-12
US20200249246A1 (en) 2020-08-06
RU2673455C2 (ru) 2018-11-27
SG11201507774YA (en) 2015-10-29
JP2020073896A (ja) 2020-05-14
WO2014147153A1 (en) 2014-09-25
US10598674B2 (en) 2020-03-24

Similar Documents

Publication Publication Date Title
HK1258520A1 (zh) 用於指導血壓下降療法的腎上腺髓質素
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
HK1221424A1 (zh) 治療癌症的藥物組合
EP2968732A4 (en) FLUID DELIVERY SYSTEM AND METHOD FOR DELIVERING FLUID TO PATIENT
FI3626270T3 (fi) Sydän- ja verisuonitautien hoito
PL2981271T3 (pl) Zastosowania terapeutyczne empagliflozyny
EP2977014A4 (en) CATHETER FOR THE TREATMENT OF SINUSITIS
EP2958964A4 (en) TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
GB201403083D0 (en) Treatment of cancer
EP3019872A4 (en) A NEW METHOD OF TARGETING GLYCOPROTEINS TO TREAT CANCER
HK1232118A1 (zh) 癌症的治療
EP2996716A4 (en) Correlates of efficacy relating to tumor vaccines
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201200262D0 (en) Therapy of breast cancer